Explore Active Pharmaceutical Ingredient Market Set To Reach US$ 225.2 Bn In Revenues By 2025

An active pharmaceutical ingredient is used in a finished pharmaceutical product (FPP), intended to carry certain pharmacological actions or otherwise have a direct effect in the diagnosis, cure, treatment, mitigation or prevention of various diseases, or in some cases in restoring, correcting or modifying human physiological functions. Sales of pharmaceutical ingredient are on the rise due to a substantial increase in high-potency API (HPAPI) and peptide API manufacturing.

A new study conducted by Persistence Market Research reveals that the US$ 151.9 Bnglobalactive pharmaceutical ingredient marketwill grow toUS$ 158.3 Bn by 2017 end, reflecting a Y-o-Y growth rate of 4.2%. This market is estimated to further increase toUS$ 225.2 Bn, expanding at aCAGR of 4.5%over the forecast period (2016 – 2025)

Get Sample Copy of Report @https://www.persistencemarketresearch.com/samples/11260

Company Profiles

• Johnson Matthey,
• Siegfried,
• Almac,
• PolyPeptide Laboratories,
• AmbioPharm, Inc.,
• Corden Pharma,
• Pepscan,
• BCN peptide,
• Provence Technologies Groups,
• SennChemicals AG,
• Avecia OligoMedicines,
• Santaris Pharma – acquired by Roche in 2014,
• ST Pharm Oligo Center,
• Cepia Sanofi,
• Biospring,
• Pfizer CenterSource,
• Symbiotec Pharma Lab Pvt. Ltd.,
• Gadea Grupo Farmacutico,
• STEROID S.p.A.,
• Dolder AG,
• Dalton Pharma Services,
• FarmaBios Spa,
• Dextra Laboratories Limited,
• GlycoSyn,
• Inalco Pharma,
• Sussex Research,
• Pfanstiehl, Inc.,
• Noramco, Inc.,
• Johnson Matthey,
• Siegfried,
• Rhodes Technologies,
• Ash Stevens,
• Fermion (public),
• FARMHISPANIA GROUP,
• Olon SpA,
• Lonza Group

Get To Know Methodology of Report @https://www.persistencemarketresearch.com/methodology/11260

PMR in its report, titled “Active Pharmaceutical Ingredient Market – Global Industry Analysis and Forecast, 2016 – 2025” has cited some of the key factors prompting the global sales of API, which include:

• Higher emphases on the development of novel therapeutics that contain high-potency active pharmaceutical ingredients (HPAPIs).

• Ramped-up investments from large-scale API manufacturers and contract manufacturers in production of high potency API.

• The lower cost of labor cost and abundance of raw materials continue to facilitate the growth of API market in the Asia region.

• Faster approvals of API based peptide and diabetes management drugs. Over the recent past, a range of peptide drugs has been approved treatment of type 2 Diabetes Mellitus including Albiglutide (GSK), Dulaglutide (Eli Lilly), Exenatide (Amylin Pharmaceuticals) and Glucagon (Xeris Pharmaceuticals).

Access Full Report @https://www.persistencemarketresearch.com/checkout/11260

According to the report, small molecule API type segment holds promising investment opportunities for market participants on account of the numerous off-patent events incurred in the last five years coupled with a strong penetration of small scale manufacturers in Asia.

On the basis region, APAC’s API market was valued atUS$ 61.4 Bn in 2016and is projected to witness the highestCAGR of 5.1 %during the forecast period to reach a valuation ofUS$ 95.6 Bn.

This is primarily owing to the leadership of China and India in SMEs as well as their strong distribution network in overseas markets especially in US, South Africa, and Europe.

Asian pharmaceuticals CMOs are competing on the basis of cost and timeline for API manufacturing and are attracting U.S.-based pharmaceuticals companies that are willing to outsource manufacturing requirements.

Meanwhile, Europe is projected to be the second fastest growing market for API and is expected to reach US$ 42.5 Bn by 2025-end. Manufacturers in Europe are prioritizing high-quality standards, advanced manufacturing installations, and high purity of intermediates (API).

Explore Extensive Coverage of PMR`sLife Sciences & Transformational HealthLandscape

Molecular Diagnostics Market –

Molecular Diagnostics MarketSegmentation by Key Players – Novartis AG, Roche Diagnostics, QIAGEN, Siemens Healthcare, Abbott Laboratories, Inc., Gen-Probe, Inc. (Hologic Inc.), Cepheid, Inc., Beckman Coulter, Inc., Becton, Dickinson & Company, Myriad Genetics, Inc., and bioMerieux.

Next-Generation Sequencing Market –

Next Generation Sequencing MarketSegmented by(By Application – Whole-genome Sequencing ,Exome Sequencing,Targeted Resequencing,De Novo Sequencing,RNA Sequencing,ChIP Sequencing,Methyl Sequencing,Others);By Technology- Targeted Sequencing & Resequencing,Whole Genome Sequencing,Whole Exome Sequencing.

Ophthalmology devises Market –

Ophthalmology devises MarketSegmentation by Key Players – Abbott Medical Optics Inc., Carl Zeiss Meditec AG, Bausch & Lomb Inc., Essilor International S.A, Ziemer Ophthalmic Systems AG and Topcon Corporation.

Intravenous Iron Drugs Market –

Intravenous (IV) Iron Drugs MarketSegmentation by Key Players- Actavis, Inc., AMAG Pharmaceuticals, Inc., Galenica Ltd., Fresenius Medical Care AG & Co. KGaA, Vifor Pharma Ltd., American Regent, Inc., Luitpold Pharmaceuticals, Inc., Pharmacosmos A/S, Rockwell Medical Technologies, Inc., and Sanofi.

Syndromes Progressive Ataxia Weakness Disorders Market –

Treatments forSyndromes of Progressive Ataxia and Weakness Disorders MarketSegmentation by Key Players- Abbott Laboratories, Acorda Therapeutics Inc., American Regent Inc., Baxter International Inc., Biogen Idec., Bristol-Myers Squibb, Cadila Healthcare Ltd., Eli Lilly and Company, Glaxosmilthkline Plc., Sanofi, Roche Holding Ltd., Pfizer Inc. and Novartis AG.

About us:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMR’s collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

305 Broadway, 7th Floor
New York City, NY 10007
United States
Ph.no. +1-646-568-7751
E-mail id-sales@persistencemarketresearch.com
Website:https://www.persistencemarketresearch.com